

Reference List

The role of vericiguat in HFrEF (or Heart Failure with reduced ejection fraction):
Will the heart go on?

HyeBin Cho, PharmD

1. Uptodate - Secondary pharmacologic therapy in heart failure with reduced ejection fraction (HFrEF) in adults. https://www.uptodate.com/contents/secondary-pharmacologic-therapy-in-heart-failure-with-reduced-ejection-fraction-hfref-in-adults?search=vericiguat&source=search_result&selectedTitle=1~3&usage_type=default&display_rank=1#H2926210056
2. Dynamed - Heart Failure With Reduced Ejection Fraction
<https://www.dynamed.com/condition/heart-failure-with-reduced-ejection-fraction>
3. M McDonald, S Virani, M Chan, et al. CCS/CHFS Heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction Can J Cardiol, 37 (2021), pp. 531-546
4. Heart failure. Heart and Stroke Foundation of Canada (2021).
<https://www.heartandstroke.ca/heart-disease/conditions/heart-failure>
5. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883-1893. (VICTORIA)
6. Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
<https://www.businesswire.com/news/home/20210120005289/en/>
7. Heart disease in Canada: Highlights from the Canadian Chronic Disease Surveillance System <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/heart-disease-canada-fact-sheet.html>